Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lithium in Autism Spectrum Disorder with Phelan-McDermid Syndrome (SHANK3 haploinsufficiency)
2017-000825-11Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of lithium carbonate in Autism Spectrum Disorder (ASD) and Phelan-McDermid syndrome (PMS), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Severity of autistic symptoms (social responsiveness). Started Jun 2018; status: completed.
02
Drugs
lithium carbonate
03
Conditions
Autism Spectrum Disorder (ASD)Phelan-McDermid syndrome (PMS)
Beyond the preview
Go deeper on 2017-000825-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000825-11.